A pharmaceutical composition comprising a TLR7 agonist and an HBV capsid assembly inhibitor, in a pharmaceutically acceptable carrier, wherein the TLR7 agonist is a compound of formula: wherein R 1 is C 1-6 alkyl; R 2 is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C 1-6 alkyl; R 3 is -NR 4 R 5, wherein R 4 is C 1-6 alkyl or C 1-6 alkoxyC 1-6 alkyl; R 5 is (C 1-6 alkyl) 2 NCOOC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxycarbonyl(C 1 - 6 alkyl)aminoC 1-6 alkyl, C 1-6 alkoxycarbonyl(phenyl)C 1-6 alkyl, C 1 - 6 alkoxycarbonylC 1-6 alkyl, C 1-6 alkoxycarbonyloxyC 1-6 alkyl, C 1-6 alkyl, C 1 - 6 alkylcarbonyl(C 1-6 alkyl)aminoC 1-6 alkyl or pyrrolidinylcarbamoyloxyC 1 - 6 alkyl; or R 4 and R 5 together with the nitrogen they are attached to form a heterocyclyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; or wherein the TLR7 agonist is a compound of formula: wherein R 4 is C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cylcoalkylC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl or pyrrolidinylC 1 - 6 alkyl; R 5 is C 1-6 alkyl, phenylC 1-6 alkyl, pyridinylC 1-6 alkyl or pyrimidinylC 1-6 alkyl, said phenylC 1-6 alkyl, pyridinylC 1-6 alkyl and pyrimidinylC 1-6 alkyl are unsubstituted or substituted by one, two or three substituents independently selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, carboxy, carbamoyl, haloC 1-6 alkyl, C 1-6 alkylsulfonyl, C 1-6 alkoxycarbonyl, C 1-6 alkoxyC 1 - 6 alkylaminocarbonyl, pyrrolidinylcarbonyl and piperidinylcarbonyl; R 6 is H; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; wherein the HBV capsid assembly inhibitor is a compound of formula: wherein R 7 is hydrogen, halogen or C 1-6 alkyl; R 8 is hydrogen or halogen; R 9 is hydrogen or halogen; R 10 is C 1-6 alkyl; R 11 is hydrogen, hydroxyC 1-6 alkyl, aminocarbonyl, C 1-6 alkoxycarbonyl or carboxy; R 12 is hydrogen, C 1-6 alkoxycarbonyl or carboxy-C m H 2m -; X is carbonyl or sulfonyl; Y is -CH 2 -, -O- or -N(R 13)-, wherein R 13 is hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl-C m H 2m -, C 1-6 alkoxycarbonyl-C m H 2m -,-C t H 2t -COOH, -haloC 1-6 alkyl-COOH, -(C 1-6 alkoxy)C 1-6 alkyl-COOH, -C 1-6 alkyl-O-C 1-6 alkyl-COOH, -C 3-7 cycloalkyl-C m H 2m -COOH, -C m H 2m -C 3-7 cycloalkyl-COOH, hydroxy-C t H 2t -, carboxyspiro[3.3]heptyl or carboxyphenyl-C m H 2m -, carboxypyridinyl-C m H 2m -; W is -CH 2 -, -C(C 1-6 alkyl) 2 -, -O- or carbonyl; n is 0 or 1; m is 0-7; t is 1-7; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof. R 1 is C 1-6 alkyl; R 2 is benzyl, said benzyl being unsubstituted or substituted by one, two or three substituents independently selected from halogen and C 1-6 alkyl; R 3 is -NR 4 R 5, wherein R 4 is C 1-6 alkyl or C 1-6 alkoxyC 1-6 alkyl; R 5 is (C 1-6 alkyl) 2 NCOOC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxycarbonyl(C 1 - 6 alkyl)aminoC 1-6 alkyl, C 1-6 alkoxycarbonyl(phenyl)C 1-6 alkyl, C 1 - 6 alkoxycarbonylC 1-6 alkyl, C 1-6 alkoxycarbonyloxyC 1-6 alkyl, C 1-6 alkyl, C 1 - 6 alkylcarbonyl(C 1-6 alkyl)aminoC 1-6 alkyl or pyrrolidinylcarbamoyloxyC 1 - 6 alkyl; or R 4 and R 5 together with the nitrogen they are attached to form a heterocyclyl; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; R 4 is C 1-6 alkyl or C 1-6 alkoxyC 1-6 alkyl; R 5 is (C 1-6 alkyl) 2 NCOOC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl, C 1-6 alkoxycarbonyl(C 1 - 6 alkyl)aminoC 1-6 alkyl, C 1-6 alkoxycarbonyl(phenyl)C 1-6 alkyl, C 1 - 6 alkoxycarbonylC 1-6 alkyl, C 1-6 alkoxycarbonyloxyC 1-6 alkyl, C 1-6 alkyl, C 1 - 6 alkylcarbonyl(C 1-6 alkyl)aminoC 1-6 alkyl or pyrrolidinylcarbamoyloxyC 1 - 6 alkyl; or R 4 and R 5 together with the nitrogen they are attached to form a heterocyclyl; R 4 is C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cylcoalkylC 1-6 alkyl, C 1-6 alkoxyC 1-6 alkyl or pyrrolidinylC 1 - 6 alkyl; R 5 is C 1-6 alkyl, phenylC 1-6 alkyl, pyridinylC 1-6 alkyl or pyrimidinylC 1-6 alkyl, said phenylC 1-6 alkyl, pyridinylC 1-6 alkyl and pyrimidinylC 1-6 alkyl are unsubstituted or substituted by one, two or three substituents independently selected from halogen, C 1-6 alkyl, C 1-6 alkoxy, cyano, carboxy, carbamoyl, haloC 1-6 alkyl, C 1-6 alkylsulfonyl, C 1-6 alkoxycarbonyl, C 1-6 alkoxyC 1 - 6 alkylaminocarbonyl, pyrrolidinylcarbonyl and piperidinylcarbonyl; R 6 is H; or pharmaceutically acceptable salt, enantiomer or diastereomer thereof; R 7 is hydrogen, halogen or C 1-6 alkyl; R 8 is hydrogen or halogen; R 9 is hydrogen or halogen; R 10 is C 1-6 alkyl; R 11 is hydrogen, hydroxyC 1-6 alkyl, aminocarbonyl, C 1-6 alkoxycarbonyl or carboxy; R 12 is hydrogen, C 1-6 alkoxycarbonyl or carboxy-C m H 2m -; X is carbonyl or sulfonyl; Y is -CH 2 -, -O- or -N(R 13)-, wherein R 13 is hydrogen, C 1-6 alkyl, haloC 1-6 alkyl, C 3-7 cycloalkyl-C m H 2m -, C 1-6 alkoxycarbonyl-C m H 2m -,-C t H 2t -COOH, -haloC 1-6 alkyl-COOH, -(C 1-6 alkoxy)C 1-6 alkyl-COOH, -C 1-6 alkyl-O-C 1-6 alkyl-COOH, -C 3-7 cycloalkyl-C m H 2m -COOH, -C m H 2m -C 3-7 cycloalkyl-COOH, hydroxy-C t H 2t -, carboxyspiro[3.3]heptyl or carboxyphenyl-C m H 2m -, carboxypyridinyl-C m H 2m -; W is -CH 2 -, -C(C 1-6 alkyl) 2 -, -O- or carbonyl; n is 0 or 1; m is 0-7; t is 1-7;